The efficacy of additional treatments in HER2-positive breast cancer patients not achieving a pCR after neoadjuvant therapy is being investigated in several studies (6), and has been reported as beneficial by the KATHERINE trial (7). Here, ERBB2 is linked to breast carcinoma.